Diabetic Mice Show Growth Hormone Hypersecretion and Receptor Resistance to Secretagogues
Background
The growth hormone (GH) axis plays a crucial role in metabolism, but its function can be disrupted in metabolic diseases like diabetes mellitus. Previous research has indicated altered GH dynamics in diabetic states, yet the specific interplay between GH secretion and tissue responsiveness to GH-stimulating agents in diabetes remains unclear. This study aimed to elucidate how streptozotocin-induced diabetes impacts both GH secretion and GH receptor sensitivity following stimulation by a GH secretagogue.
Results
Diabetic mice exhibited significantly higher basal GH levels, averaging 3.5 ng/mL compared to 1.2 ng/mL in controls (p<0.001). Following GHRP-6 administration, diabetic mice showed an exaggerated GH secretory response, with peak GH levels reaching 58.7 ng/mL compared to 31.2 ng/mL in healthy controls (p<0.001), representing a 1.9-fold higher peak. Despite this hypersecretion, liver GH receptor mRNA expression was reduced by 45% in diabetic mice (p<0.01), and STAT5 phosphorylation was diminished by 38% compared to controls (p<0.05). Serum IGF-1 levels, a key mediator of GH action, were 25% lower in diabetic mice even after GHRP-6 stimulation (p<0.05).
Why It Matters
This study highlights a critical paradox in diabetes: GH hypersecretion coexisting with peripheral GH receptor resistance. This finding suggests that the body attempts to compensate for impaired GH signaling by increasing GH production, but target tissues remain unresponsive. Understanding this dysregulation could lead to novel therapeutic strategies for managing metabolic complications in diabetes. Specifically, these insights could inform the development of targeted therapies that either modulate GH secretion or enhance GH receptor sensitivity in diabetic patients, potentially improving metabolic control. Further research, including human trials, is warranted to translate these findings into clinical practice.